Annual report pursuant to Section 13 and 15(d)

Intangible Assets - Narrative (Details)

v3.20.4
Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jan. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Intangible assets        
Amortization of intangible assets   $ 153 $ 123 $ 77
Impairment of intangible assets $ 104      
Sales and Marketing Expense        
Intangible assets        
Royalty fees included in sales and marketing expense   $ 2,289 $ 2,119 $ 1,661
License agreements        
Intangible assets        
Notice period for termination of license agreements   60 days    
Minimum royalty of agreements   $ 13    
Milestone fee upon receiving a Phase II Small Business Innovation Research   15    
Milestone fee upon FDA approval   2    
Milestone fee upon first commercial use of certain licensed technology   25    
Milestone fee upon first use to manufacture products that utilize certain technology not currently incorporated into AxoGen products   $ 10    
Minimum | License agreements        
Intangible assets        
Amortization period of intangible assets   17 years    
Royalty fees range under the license agreements   1.00%    
Maximum | License agreements        
Intangible assets        
Amortization period of intangible assets   20 years    
Royalty fees range under the license agreements   3.00%    
Royalty stack cap for royalties paid to more than one licensor for sales of the same product   3.75%    
Maximum | Patents        
Intangible assets        
Amortization period of intangible assets   20 years